ARTICLE | Clinical News

Halozyme starts Phase Ib/II of PEGPH20 plus Tecentriq

December 8, 2017 7:04 PM UTC

In October, Halozyme Therapeutics Inc. (NASDAQ:HALO) began the Phase Ib/II HALO-110-101 trial to evaluate PEGPH20 in combination with standard chemotherapy with or without Tecentriq atezolizumab to treat previously untreated, unresectable, locally advanced, or metastatic cholangiocarcinoma and gallbladder adenocarcinoma in patients with high hyaluronan levels.

The first run-in portion of the open-label, international trial will evaluate safety and pharmacokinetics in about 12 patients. The second expansion portion will enroll 50 additional patients. The primary endpoint of the expansion portion is overall response rate (ORR) and secondary endpoints include progression-free survival (PFS) and duration of response. Patients will receive 3 µg/kg PEGPH20 on days 1, 8 and 15...

BCIQ Target Profiles